The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity

The neonatal Fc receptor (FcRn) is expressed by cells of epithelial, endothelial and myeloid lineages and performs multiple roles in adaptive immunity. Characterizing the FcRn/IgG interaction is fundamental to designing therapeutic antibodies because IgGs with moderately increased binding affinities for FcRn exhibit superior serum half-lives and efficacy. It has been hypothesized that 2 FcRn molecules bind an IgG homodimer with disparate affinities, yet their affinity constants are inconsistent across the literature. Using surface plasmon resonance biosensor assays that eliminated confounding experimental artifacts, we present data supporting an alternate hypothesis: 2 FcRn molecules saturate an IgG homodimer with identical affinities at independent sites, consistent with the symmetrical arrangement of the FcRn/Fc complex observed in the crystal structure published by Burmeister et al. in 1994. We find that human FcRn binds human IgG1 with an equilibrium dissociation constant (KD) of 760 ± 60 nM (N = 14) at 25°C and pH 5.8, and shows less than 25% variation across the other human subtypes. Human IgG1 binds cynomolgus monkey FcRn with a 2-fold higher affinity than human FcRn, and binds both mouse and rat FcRn with a 10-fold higher affinity than human FcRn. FcRn/IgG interactions from multiple species show less than a 2-fold weaker affinity at 37°C than at 25°C and appear independent of an IgG's variable region. Our in vivo data in mouse and rat models demonstrate that both affinity and avidity influence an IgG's serum half-life, which should be considered when choosing animals, especially transgenic systems, as surrogates.

[1]  J. Dumont,et al.  Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics , 2015, Critical reviews in biotechnology.

[2]  T. Tiller,et al.  Characterization and screening of IgG binding to the neonatal Fc receptor , 2014, mAbs.

[3]  Herren Wu,et al.  Structural Insights into Neonatal Fc Receptor-based Recycling Mechanisms , 2014, The Journal of Biological Chemistry.

[4]  A. Rajpal,et al.  Determining the Binding Affinity of Therapeutic Monoclonal Antibodies towards Their Native Unpurified Antigens in Human Serum , 2013, PloS one.

[5]  A. Drake,et al.  Biacore surface matrix effects on the binding kinetics and affinity of an antigen/antibody complex. , 2012, Analytical biochemistry.

[6]  Pavel Strop,et al.  Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair. , 2012, Journal of molecular biology.

[7]  J. Andersen,et al.  Anti-carcinoembryonic Antigen Single-chain Variable Fragment Antibody Variants Bind Mouse and Human Neonatal Fc Receptor with Different Affinities That Reveal Distinct Cross-species Differences in Serum Half-life* , 2012, The Journal of Biological Chemistry.

[8]  N. Fischer,et al.  Robust recombinant FcRn production in mammalian cells enabling oriented immobilization for IgG binding studies. , 2012, Journal of immunological methods.

[9]  B. Carr,et al.  Monoclonal Antibodies with Identical Fc Sequences Can Bind to FcRn Differentially with Pharmacokinetic Consequences , 2011, Drug Metabolism and Disposition.

[10]  A. Rajpal,et al.  Expanding the ProteOn XPR36 biosensor into a 36-ligand array expedites protein interaction analysis. , 2011, Analytical biochemistry.

[11]  T. Igawa,et al.  Reduced elimination of IgG antibodies by engineering the variable region. , 2010, Protein engineering, design & selection : PEDS.

[12]  F. Theil,et al.  Pharmacokinetics of Humanized Monoclonal Anti-Tumor Necrosis Factor-α Antibody and Its Neonatal Fc Receptor Variants in Mice and Cynomolgus Monkeys , 2010, Drug Metabolism and Disposition.

[13]  Tetsu Kobayashi,et al.  Importance of Neonatal FcR in Regulating the Serum Half-Life of Therapeutic Proteins Containing the Fc Domain of Human IgG1: A Comparative Study of the Affinity of Monoclonal Antibodies and Fc-Fusion Proteins to Human Neonatal FcR , 2010, The Journal of Immunology.

[14]  I. Sandlie,et al.  Cross-species Binding Analyses of Mouse and Human Neonatal Fc Receptor Show Dramatic Differences in Immunoglobulin G and Albumin Binding* , 2009, The Journal of Biological Chemistry.

[15]  J. Marvin,et al.  Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates , 2009, The Journal of Immunology.

[16]  S. Akilesh,et al.  FcRn: the neonatal Fc receptor comes of age , 2007, Nature Reviews Immunology.

[17]  A. Datta-Mannan,et al.  Humanized IgG1 Variants with Differential Binding Properties to the Neonatal Fc Receptor: Relationship to Pharmacokinetics in Mice and Primates , 2007, Drug Metabolism and Disposition.

[18]  David G Myszka,et al.  Exploring "one-shot" kinetics and small molecule analysis using the ProteOn XPR36 array biosensor. , 2006, Analytical biochemistry.

[19]  P. Bjorkman,et al.  Ligand Valency Affects Transcytosis, Recycling and Intracellular Trafficking Mediated by the Neonatal Fc Receptor , 2006, Traffic.

[20]  A. West,et al.  FcRn mediates elongated serum half-life of human IgG in cattle. , 2006, International immunology.

[21]  S. Morrison,et al.  Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life. , 2006, Molecular immunology.

[22]  Bruce Tidor,et al.  Quantitative methods for developing Fc mutants with extended half-lives. , 2005, Biotechnology and bioengineering.

[23]  A. Bitonti,et al.  Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[24]  A. Kossiakoff,et al.  Site2 binding energetics of the regulatory step of growth hormone–induced receptor homodimerization , 2003, Protein science : a publication of the Protein Society.

[25]  R. Ober,et al.  Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. , 2001, International immunology.

[26]  Leonard G. Presta,et al.  High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR* , 2001, The Journal of Biological Chemistry.

[27]  A. West,et al.  Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor(,). , 2000, Biochemistry.

[28]  E. Ward,et al.  Sedimentation equilibrium analysis of recombinant mouse FcRn with murine IgG1. , 1999, Molecular immunology.

[29]  P. Bjorkman,et al.  Characterization of the 2:1 complex between the class I MHC-related Fc receptor and its Fc ligand in solution. , 1999, Biochemistry.

[30]  D. Myszka,et al.  Improving biosensor analysis , 1999, Journal of molecular recognition : JMR.

[31]  L. Williamson,et al.  Recombinant human IgG molecules lacking Fcγ receptor I binding and monocyte triggering activities , 1999, European journal of immunology.

[32]  D. M. Penny,et al.  Stoichiometry of the interaction between the major histocompatibility complex-related Fc receptor and its Fc ligand. , 1999, Biochemistry.

[33]  B. Ober,et al.  The stoichiometry and affinity of the interaction of murine Fc fragments with the MHC class I-related receptor, FcRn. , 1996, Molecular immunology.

[34]  P. Bjorkman,et al.  Effects of receptor dimerization on the interaction between the class I major histocompatibility complex-related Fc receptor and IgG. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Pamela J. Bjorkman,et al.  Crystal structure of the complex of rat neonatal Fc receptor with Fc , 1994, Nature.

[36]  P. Bjorkman,et al.  Crystallization and stoichiometry of binding of a complex between a rat intestinal Fc receptor and Fc. , 1993, Journal of molecular biology.

[37]  P. Bjorkman,et al.  Expression and crystallization of a soluble and functional form of an Fc receptor related to class I histocompatibility molecules. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[38]  S. Hobbs,et al.  Binding of subclasses of rat immunoglobulin G to detergent-isolated Fc receptor from neonatal rat intestine. , 1987, The Journal of biological chemistry.

[39]  J. Cambier,et al.  Transepithelial transport of maternal antibody: purification of IgG receptor from newborn rat intestine. , 1985, Journal of immunology.

[40]  D. Roopenian,et al.  Human FcRn transgenic mice for pharmacokinetic evaluation of therapeutic antibodies. , 2010, Methods in molecular biology.